Abstract

Chronic lymphoproliferative disorders (CLPD) are a heterogeneous group of diseases characterized by uncontrolled production of lymphocytes that cause monoclonal lymphocytosis, lymphadenopathy, bone marrow infiltration, and specific immunophenotypic profile. CLPDs are relatively uncommon in Asian populations, constituting around 2% of all leukemias. The frequency of CLPDs shows geographical variations owing to distinct genetic or environmental factors that play a role in the development of these diseases. To determine the frequency and distribution of various B-cell CLPDs (B-CLPDs) diagnosed at a large tertiary care center in north India. We conducted a retrospective analysis of all patients diagnosed with B-CLPD at the All India Institute of Medical Sciences, New Delhi, between the years 2015 and 2019 to determine the prevalence, frequency, and distribution of B-CLPD in our patient population. The diagnosis of B-CLPD was based on morphologic and immunophenotypic criteria proposed by the World Health Organization (WHO) in 2008. A total of 439 patients were diagnosed with B-CLPD at our center with a median age of 57 years, and male:female ratio was 2.5:1. Chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia was the most common form, constituting 58.31% of all. Other B-CLPDs identified in our cohort were follicular lymphoma (FL) 13.43%, mantle cell lymphoma (MCL) 6.83%, marginal zone lymphoma 6.37%, lymphoplasmacytic lymphoma/Waldenström macroglobulinemia 2.51%, mucosa-associated lymphatic tissue lymphoma 2.05%, hairy cell leukemia 1.59%, prolymphocytic leukaemia 0.68% and rest 8.6% were B-CLPD unclassified. This is one of the largest studies from India. CLL is the most common B-CLPD followed by FL and MCL.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.